Boston Scientific Corporation (BSX)
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Boston Scientific Stock Gains From Market Expansion, Innovation
BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options.
Why The Fundamentals Make Me Bullish On Boston Scientific
Medical devices maker Boston Scientific should continue to grow profitably through the next several years. Backing that bullishness is its history, good margins, pipeline, capital allocation, and more. While all other Seeking Alpha analysts have rated it a Hold this year, I have a Buy rating and expect the price to grow nearly 15% in the coming year.
Looking for a Growth Stock? 3 Reasons Why Boston Scientific (BSX) is a Solid Choice
Boston Scientific (BSX) possesses solid growth attributes, which could help it handily outperform the market.
Buy 5 S&P 500 Stocks to Tap Potential Short-Term Price Appreciation
These five stocks have provided double-digit returns year to date. Despite the rally, these stocks have double-digit upside potential for the short term.
Why is Boston Scientific Stock Trading Lower On Wednesday?
On Wednesday, Boston Scientific Corporation BSX released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe, symptomatic aortic stenosis at risk of open-heart surgery.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
Here is how Boston Scientific (BSX) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have performed compared to their sector so far this year.
Boston Scientific Profit Falls Even as Demand for Its Heart Products Surges
Boston Scientific (BSX) shares fell Wednesday when the medical equipment manufacturer's third-quarter profit fell and its GAAP earnings per share (EPS) came in short of its guidance.
BSX Q3 Earnings Top, Stock Down in Premarket as Operating Margin Falls
Boston Scientific registers year-over-year improvement in sales, indicating solid market share gains in legacy businesses despite macroeconomic odds.
Boston Scientific Corporation (BSX) Q3 2024 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX ) Q3 2024 Earnings Conference Call October 23, 2024 8:00 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Michael Mahoney - Chairman and Chief Executive Officer Daniel Brennan - Executive Vice President and Chief Financial Officer Kenneth Stein - Senior Vice President, Global Chief Medical Officer Conference Call Participants Robert Marcus - JPMorgan Joanne Wuensch - Citigroup Inc. Lawrence Biegelsen - Wells Fargo Securities Frederick Wise - Stifel, Nicolaus & Company David Roman - Goldman Sachs Patrick Wood - Morgan Stanley Travis Steed - Barclays Bank Danielle Antalffy - UBS Anthony Petrone - Mizuho Group Vijay Kumar - Evercore ISI Matt Miksic - Barclays Joshua Jennings - TD Cowen Matthew O'Brien - Piper Sandler Operator Good morning and welcome to the Boston Scientific Third Quarter 2024 Earnings Call. All participants will be in listen-only mode.
Compared to Estimates, Boston Scientific (BSX) Q3 Earnings: A Look at Key Metrics
The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
